Strasbourg, France, May 15, 2014 - Transgene SA (Euronext Paris: TNG), a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, today provided an update on TG6002, Transgene's proprietary oncolytic immunotherapy being developed for the treatment of solid tumors. TG6002 was discovered and designed by Transgene, which owns all development and commercialization rights to the program. TG6002 is currently in pre-clinical testing and has shown activity in several human tumor mouse models. The Company currently plans to initiate human clinical testing in 2015.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.34 (c)||0.91%||43 338|